N-acetylcysteine for Parkinson's disease: a translational systematic review of mechanistic and early clinical data.
Anas Mohammad, Mohammad Ibrahim, Moeez Akram et al.
✦ AI-curated · Sources linked
In 30 seconds
This PRISMA-compliant systematic review assessed preclinical and prospective clinical evidence on N-acetylcysteine (NAC) for Parkinson’s disease, including motor outcomes, dopaminergic imaging, glutathione and safety. Twelve studies met the criteria. Animal models showed consistent neuroprotection, while human studies indicated that NAC could increase brain glutathione or reach cerebrospinal fluid. In two open-label trials involving 65 participants, UPDRS scores improved by ~ 13% and dopamine transporter signal increased by 4-9% over three months. The authors conclude that larger randomised controlled trials are needed to establish efficacy and disease-modifying potential.
Key findings
- Across two open-label trials (n = 65), UPDRS scores improved by ~ 13% over three months.
- Dopamine transporter signal increased by 4-9% over three months in the open-label trials.
- Intravenous NAC raised brain glutathione levels, and high-dose oral NAC reached CSF.
- No serious adverse events were attributed to NAC; preclinical models showed consistent neuroprotection.
Why it matters
The review brings together mechanistic, animal and early human evidence for a therapy intended to address oxidative stress in Parkinson’s disease. The reported biomarker and clinical changes provide a rationale for further study, but the available human findings are preliminary and do not establish that NAC improves symptoms or slows disease progression.
What to keep in mind
The clinical evidence came from two open-label trials, and the review concludes that larger randomised controlled trials are needed. The reported three-month outcomes do not establish longer-term benefit or disease modification.